Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

nChroma Bio stops its only clinical study early, lays off 50%

A couple of years ago, two Boston-area biotech CEOs decided to merge their startups, hoping to survive a down market for genetic medicine companies. Jeff Walsh, the CEO of that combined company, nChroma Bio,

We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.

Read the original at endpoints.news →

More in Health & Medicine

More from Wednesday 18 November →